modifi
live
viru
mlv
vaccin
commonli
use
reduc
impact
porcin
reproduct
respiratori
syndrom
prr
limit
efficaci
achiev
field
condit
evalu
impact
maternallyderiv
neutral
antibodi
mdna
vaccin
efficaci
prr
viru
prrsv
challeng
piglet
low
high
mdna
level
deriv
commerci
pig
herd
move
experiment
facil
vaccin
v
mlv
vaccin
week
age
woa
unexpectedli
low
vaccin
detect
piglet
postvaccin
pv
v
piglet
receiv
second
vaccin
woa
five
week
pv
piglet
inocul
field
strain
evalu
vaccin
protect
mingl
h
later
noninocul
piglet
similar
immun
statu
assess
viral
transmiss
vaccin
strain
detect
pv
av
piglet
pv
av
piglet
respect
pv
av
piglet
seroconvert
signific
ifng
respons
induct
group
challeng
compar
inocul
group
viremia
lower
day
postinfect
wherea
viremia
significantli
reduc
av
piglet
lower
transmiss
rate
estim
group
versu
av
group
respect
investig
low
vaccin
strain
detect
first
vaccin
suggest
relationship
ifna
level
vaccin
strain
detect
piglet
show
mdna
impair
vaccin
efficaci
prrsv
inocul
contact
piglet
probabl
reduc
vaccin
replic
ifna
may
also
interfer
prrsv
vaccin
new
data
could
help
improv
vaccin
protocol
porcin
reproduct
respiratori
syndrom
prr
caus
small
rna
viru
member
arterivirida
famili
one
costli
diseas
swine
product
worldwid
western
europ
prr
viru
main
circul
prrsv
speci
prrsv
infect
character
reproduct
failur
sow
respiratori
disord
growth
retard
increas
mortal
grow
pig
prrsv
predispos
pig
secondari
infect
associ
porcin
respiratori
diseas
complex
limit
impact
prr
modifi
live
viru
mlv
vaccin
base
cell
cultur
attenu
prrsv
strain
routin
use
gilt
sow
grow
pig
control
prr
field
still
challeng
partial
protect
achiev
mainli
limit
clinic
sign
lesion
howev
experiment
condit
vaccin
provid
good
protect
prrsv
challeng
piglet
control
viremia
infect
pig
decreas
transmiss
contact
pig
unlik
experiment
condit
field
condit
vaccin
piglet
gener
born
prrsv
infect
expos
vaccin
sow
sinc
commonli
vaccin
prrsv
prevent
prrsv
circul
farrow
unit
improv
farrow
http
elsevi
ltd
right
reserv
rate
consequ
high
level
maternallyderiv
antibodi
mda
prrsv
frequent
detect
piglet
vaccin
wean
among
mda
maternallyderiv
neutral
antibodi
mdna
protect
suckl
piglet
prrsv
infect
first
week
life
prevent
viremia
wean
piglet
howev
recent
demonstr
neg
impact
mdna
prrsv
vaccin
piglet
vaccin
week
age
woa
mlv
vaccin
studi
vaccin
strain
replic
impair
prrsv
antibodi
ifngsecret
cell
product
inhibit
week
postvaccin
pv
piglet
high
level
mdna
interfer
mdna
postvaccin
immun
respons
suggest
weak
protect
prrsv
infect
piglet
vaccin
presenc
high
mdna
level
could
explain
lower
vaccin
efficaci
observ
field
previou
studi
report
vaccin
piglet
high
mda
level
impact
vaccin
efficaci
neutral
antibodi
na
consid
present
studi
piglet
vaccin
presenc
low
high
mdna
level
challeng
wild
assess
impact
mdna
efficaci
mlv
vaccin
experi
perform
use
larg
white
landrac
pietrain
piglet
select
convent
farrowtofinish
herd
free
prrsv
circul
grow
pig
sow
maintain
mlv
mass
vaccin
sow
porcili
prr
msd
franc
order
keep
certain
level
immun
case
prrsv
reintroduct
herd
start
studi
absenc
prrsv
circul
individu
check
elisa
pig
sampl
end
fatten
period
pcr
wean
piglet
use
sampl
pool
anim
piglet
use
studi
born
sow
high
prrsv
na
titr
sow
low
prrsv
na
titer
woa
blood
collect
piglet
order
assign
accord
prrsvspecif
mdna
level
high
level
mean
na
titr
low
level
mean
na
titr
woa
studi
piglet
wean
transfer
ans
biosafeti
level
anim
facil
ploufragan
randomli
distribut
accord
statu
weight
gender
fig
piglet
per
group
absenc
prrsv
infect
piglet
woa
check
rtpcr
use
sampl
pool
anim
decay
mda
individu
evalu
woa
afterward
mean
na
titer
nolong
detect
na
piglet
vaccin
v
twice
woa
use
one
dose
porcili
prr
vaccin
msd
franc
intramuscular
inject
neck
use
syring
needl
mm
vaccin
lot
week
postfirst
vaccin
pv
half
piglet
inocul
tcid
pig
finister
strain
nasal
inocul
use
syring
without
needl
ml
per
nostril
day
noninocul
contact
c
piglet
immun
statu
mingl
inocul
piglet
pen
c
piglet
pen
eight
unvaccin
noninocul
piglet
assign
control
group
due
wane
mdna
time
prrsv
inocul
piglet
control
group
undetect
prr
antibodi
level
vnt
elisa
test
data
shown
ident
immun
statu
allow
us
mingl
result
piglet
control
group
postinocul
period
blood
sampl
collect
jugular
vein
week
week
pv
individu
detect
viremia
monitor
humor
cellular
immun
respons
challeng
clinic
sign
record
daili
blood
collect
twice
week
anim
euthan
day
postinocul
pi
individu
quantifi
finister
strain
viremia
evalu
immun
respons
experi
author
french
prrsvspecif
na
quantifi
serum
cell
target
vaccin
strain
previous
describ
challeng
vaccin
strain
genom
detect
use
adiavet
tm
prr
realtim
rtpcr
kit
adiagen
saintbrieuc
franc
challeng
specif
detect
finister
strain
genom
assess
qrtpcr
describ
rose
et
al
prrsvspecif
ifngsecret
cell
ifngsc
quantifi
previous
describ
use
h
prrsv
stimul
pbmc
multipl
infect
either
vaccin
strain
finister
strain
number
spot
per
well
count
use
immunospot
uv
analyz
ctl
shaker
height
oh
usa
antibodi
prrsv
detect
serum
use
prr
ab
elisa
test
idexx
laboratori
liebefeld
switzerland
sampletoposit
sp
ratio
valu
equal
greater
consid
posit
porcin
ifna
quantifi
serum
use
inhous
elisa
test
previous
describ
data
calcul
area
curv
auc
compar
group
use
kruskalw
test
p
post
hoc
pairwis
comparison
perform
use
holm
test
adjust
pvalu
comparison
accord
number
test
conduct
p
relationship
blood
genom
viral
load
number
ifngsc
inocul
anim
postchalleng
followup
period
assess
spearman
correl
test
p
estim
transmiss
paramet
base
seir
model
individu
consid
accord
virolog
result
suscept
uninfect
expos
infect
without
viru
excret
infecti
infect
viru
excret
remov
protect
without
role
infecti
process
durat
latenc
period
transmiss
rate
viru
estim
bayesian
infer
use
metropolishast
algorithm
previous
use
converg
assess
visual
inspect
diagnost
test
gelmanrubin
autocorrel
heidelberg
pv
vaccin
strain
detect
piglet
fig
second
vaccin
thu
perform
pv
condit
first
pv
piglet
virem
wherea
av
piglet
differ
av
maintain
pv
twofold
fewer
virem
piglet
av
compar
piglet
fig
signific
ifng
respons
observ
pv
pv
piglet
wherea
av
group
number
ifngsc
significantli
increas
pv
fig
regard
seroconvers
piglet
except
one
show
detect
prrsv
antibodi
level
serum
pv
fig
time
av
piglet
seroposit
fig
prrsv
challeng
mild
clinic
sign
observ
unvaccin
inocul
vi
piglet
show
signific
rais
rectal
temperatur
day
postchalleng
compar
unchalleng
control
piglet
statist
differ
observ
growth
perform
supplementari
fig
vaccin
inocul
pig
whatev
mdna
statu
avi
signific
differ
observ
vi
group
rectal
temperatur
growth
perform
lower
finister
strain
viral
load
detect
piglet
compar
anim
auc
equival
tcid
ml
week
equival
tcid
ml
week
respect
p
lower
valu
pi
p
fig
differ
observ
vi
group
vaccin
group
mean
viremia
durat
shorten
day
day
avi
day
anim
significantli
vaccin
induc
earli
ifng
respons
finister
strain
pi
inocul
piglet
v
group
fig
even
though
ifngsc
detect
compar
avi
piglet
differ
signific
interestingli
consid
inocul
pig
pi
period
neg
correl
could
establish
number
ifngsc
finister
strain
genom
load
serum
r
p
na
detect
pi
inocul
pig
pi
piglet
quantifi
na
titr
compar
avi
vi
anim
supplementari
fig
reduct
viremia
observ
c
contact
pig
compar
vc
piglet
auc
equival
tcid
ml
week
equival
tcid
ml
week
respect
p
avc
piglet
fig
pi
finister
strain
yet
detect
c
piglet
wherea
first
posit
piglet
identifi
pi
contact
group
fig
mean
viremia
durat
shorten
day
compar
day
avc
vc
group
respect
finister
strain
detect
unvaccin
piglet
vaccin
group
contact
anim
becam
infect
except
one
av
c
pig
fig
avc
piglet
remain
uninfect
seroconvert
postvaccin
consid
outlier
anim
protect
prrsv
infect
role
transmiss
process
estim
transmiss
rate
av
group
compar
group
av
respect
tabl
group
estim
transmiss
rate
reduc
order
understand
unexpectedli
low
vaccin
viremia
detect
piglet
first
vaccin
ifna
level
assess
serum
sampl
collect
pv
present
experi
experi
b
compar
collect
time
previou
studi
experi
vaccin
viremia
detect
anim
vaccin
result
show
significantli
higher
level
ifna
piglet
experi
b
experi
fig
relationship
could
thu
hypothes
high
ifna
level
detect
time
vaccin
low
subsequ
vaccin
strain
detect
fig
vaccin
program
hardli
erad
prrsv
circul
farm
wherea
prr
mlv
show
good
efficaci
piglet
control
prrsv
transmiss
experiment
condit
previou
studi
demonstr
interfer
mdna
postvaccin
immun
respons
induct
week
postvaccin
suggest
neg
impact
mdna
vaccin
efficaci
piglet
test
hypothesi
mlv
vaccin
piglet
low
high
level
mdna
challeng
field
strain
despit
anim
vaccin
twice
present
studi
vaccin
viremia
detect
one
av
piglet
wherea
detect
piglet
pv
accord
previou
data
confirm
interfer
mdna
vaccin
viremia
experi
also
indic
piglet
low
level
mdna
vaccin
induc
signific
humor
cellular
postvaccin
immun
respons
also
corrobor
previou
result
present
studi
observ
lower
interfer
mdna
postvaccin
immun
respons
compar
previou
one
report
fablet
complet
impair
observ
week
pv
reduc
interfer
could
ascrib
need
vaccin
piglet
twice
ensu
decreas
mdna
level
time
second
vaccin
time
first
vaccin
woa
decreas
mdna
level
alreadi
high
mean
na
titr
present
studi
compar
one
fablet
studi
despit
slightli
reduc
postvaccin
differ
v
observ
present
studi
postchalleng
result
demonstr
first
time
prrsv
vaccin
effect
piglet
low
level
mdna
low
virul
strain
use
challeng
anim
limit
evalu
vaccin
efficaci
virolog
paramet
previous
demonstr
porcili
prr
vaccin
protect
spf
piglet
mda
challeng
low
virul
strain
decreas
viremia
inocul
piglet
consider
reduc
transmiss
finister
strain
contact
piglet
present
studi
challeng
strain
viral
load
significantli
reduc
inocul
contact
piglet
compar
unvaccin
piglet
similar
unpublish
studi
also
show
prrsv
challeng
strain
viremia
significantli
reduc
inocul
piglet
compar
av
anim
first
week
pi
supplementari
fig
studi
vaccin
viremia
also
detect
piglet
postvaccin
second
vaccin
perform
challeng
indic
neg
impact
mdna
prr
vaccin
efficaci
also
occur
absenc
vaccin
viremia
usual
singl
vaccin
protocol
implement
field
use
closelyrel
approach
jeong
et
al
evalu
efficaci
mlv
vaccin
piglet
maternallyderiv
antibodi
mda
impact
mda
observ
jeong
studi
piglet
mda
vaccin
mdagroup
includ
thu
preclud
clearli
evalu
impact
mda
vaccin
efficaci
balasch
et
al
recent
show
vaccin
piglet
use
new
mlv
presenc
mda
induc
partial
protect
challeng
day
pv
balasch
studi
na
quantifi
piglet
vaccin
time
also
absenc
comparison
vaccin
piglet
without
mdna
limit
conclus
studi
interfer
mda
vaccin
efficaci
previous
demonstr
mani
swine
diseas
use
kill
vaccin
porcin
circoviru
type
similar
studi
compar
vaccin
efficaci
piglet
low
high
mda
level
show
signific
reduct
percentag
pcr
posit
anim
group
compar
av
group
day
postchalleng
use
mlv
classic
swine
fever
piglet
high
mdna
level
vaccin
die
challeng
week
age
wherea
piglet
low
mdna
level
surviv
challeng
addit
consid
contact
anim
result
also
demonstr
mdna
decreas
prr
vaccin
efficaci
viru
transmiss
present
studi
prr
vaccin
piglet
reduc
transmiss
rate
finister
strain
twofold
compar
rate
estim
vgroup
magnitud
effect
substanti
lower
found
previou
studi
tenfold
reduc
transmiss
rate
vaccin
spf
pig
non
mda
one
possibl
explan
discrep
may
intraderm
rout
id
use
vaccin
previou
work
immun
rout
previous
shown
induc
enhanc
cellmedi
immun
respons
prrsv
exposur
lower
respiratori
clinic
score
compar
im
vaccin
better
immun
respons
especi
mucos
site
elicit
id
immun
may
limit
viral
replic
respiratori
tract
thu
reduc
viru
excret
transmiss
fablet
et
al
studi
vaccin
viremia
detect
piglet
pv
wherea
piglet
present
studi
first
vaccin
explor
unexpect
result
attempt
investig
origin
low
vaccin
replic
display
piglet
vaccin
woa
vaccin
strain
titrat
problem
detect
ifna
recent
shown
strongli
inhibit
replic
genotyp
prr
mlv
hypothes
cytokin
could
respons
inhibit
vaccin
replic
piglet
inde
level
ifna
detect
piglet
present
studi
woa
much
higher
previou
studi
rang
concentr
shown
abl
complet
inhibit
prr
mlv
replic
bring
preliminari
conclus
seem
ifna
concentr
like
interfer
prr
mlv
replic
could
achiev
piglet
field
condit
absenc
suitabl
sampl
right
type
collect
right
time
explor
abl
identifi
caus
increas
ifna
level
howev
cytokin
known
produc
respons
mani
viral
infect
swine
influenza
porcin
respiratori
coronaviru
could
infect
piglet
wean
frequent
vaccin
prrsv
result
potenti
viral
interfer
prr
mlv
vaccin
may
anoth
possibl
explan
limit
prr
mlv
vaccin
efficaci
observ
field
result
confirm
mdna
impair
prr
vaccin
strain
replic
postvaccin
immun
respons
furthermor
demonstr
first
time
impair
immun
respons
result
decreas
vaccin
efficaci
base
virolog
paramet
evalu
low
virul
prrsv
challeng
use
virul
strain
challeng
anim
may
bring
clinic
argument
regard
reduc
vaccin
efficaci
presenc
high
level
mdna
unexpectedli
also
show
factor
ifna
may
interfer
prr
mlv
vaccin
research
need
explor
possibl
viral
interfer
phenomenon
toward
prr
mlv
vaccin
end
low
efficaci
prr
vaccin
observ
field
could
thu
result
endogen
mda
well
exogen
viral
infect
factor
rtpcr
one
week
postvaccin
pv
experi
b
pv
experi
data
report
mean
result
obtain
piglet
group
differ
letter
b
indic
group
significantli
differ
p
postvaccin
time
relat
first
vaccin
week
pv
